Építés alatt – nem éles oldal
Belépés
VisszavonvaFázis nélkül

Safety and Efficacy of IrisFIT™ Patent Foramen Ovale Occluders

A legfontosabb adatok

Ki végzi
Lifetech Scientific (Shenzhen) Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Visszavonva
Kezdés
2022. ápr. 12.
Várható befejezés
2028. márc. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Iris FIT™ PFO closure system
A regiszteradat frissítve
2023. március 14.
Miért állt le
Company policy

Ki vehet részt

Életkor
18 év – 60 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients aged 18-60 years
  • Be able to understand the purpose of the experiment, voluntarily participate in the experiment and sign the informed consent
  • Patent foramen ovale was confirmed by chest ultrasound (TTE) or esophageal ultrasound (TEE)
  • The presence of a large right-to-left shunt was confirmed by right aspiration angiography (cTTE or cTCD)
  • It meets the clinical status of patent foramen ovale plugging indication, and at least one of the following conditions exists:; Cryptogenic stroke complicated with patent foramen ovale, combined with one or more clinical risk factors; Cryptogenic stroke complicated with patent foramen ovale, combined with one or more anatomical risk factors of patent foramen ovale; Cryptogenic stroke complicated with patent foramen ovale, with clear deep vein thrombosis or pulmonary embolism, and not suitable for anticoagulant therapy; Cryptogenic stroke complicated with patent foramen ovale, but still recurred with antiplatelet or anticoagulant therapy

Ki nem vehet részt

  • Mitral/aortic disease: including mitral stenosis or severe mitral regurgitation of any cause, severe aortic stenosis or severe aortic regurgitation, mitral or aortic valve vegetations or prior valve replacement surgery
  • Participate in clinical trials of other drugs or medical devices within three months
  • intracardiac thrombosis or tumor, intracardiac neoplasm
  • acute myocardial infarction or unstable angina within 6 months
  • Left ventricular aneurysm formation or left ventricular wall movement disorder
  • Patients with active endocarditis or other untreated infections or other hemorrhagic diseases
  • Pulmonary hypertension or patent foramen ovale was a special channel
  • Uncontrolled hypertension (> 180/100 mmHg)
  • Contraindication of antiplatelet or anticoagulant therapy, such as severe bleeding within 3 months, obvious retinopathy, history of other intracranial bleeding, and obvious intracranial diseases
  • Coronary heart disease, hypertension, diabetes and other vascular diseases that are poorly controlled by drugs or other means
  • Thrombosis exists at the location or route of implantation
  • Malignant neoplasms or other diseases with a life expectancy of less than 2 years
  • Dilated cardiomyopathy, LVEF < 35%, or other severe heart failure
  • liver and kidney function impairment (ALT or AST > 3 times the upper limit of normal value, serum creatinine (Cr) > 2 times the upper limit of normal value)
  • Carotid atherosclerotic stenosis was determined by the investigator based on CT or vascular ultrasound (> 50%)
  • Large cerebral infarction occurred within 4 weeks (MR/CT or DWI image ASPECTS score <6 points or infarction volume ≥70 ml or infarction area > 1/3 middle cerebral artery blood supply area)
  • Patients with right-to-left shunt due to other causes, including atrial septal defect or perforated diaphragm
  • Atrial fibrillation/atrial flutter (chronic or intermittent)
  • pregnant or planning to become pregnant during the trial
  • The investigator determined that the patient was not suitable for implantation of PFO occluder (for example, the diameter of the base of the atrial septal tumor ≥25mm and the size of the foramen ovale ≥5mm) or the patient has contraindications for implantation of PFO occluder
  • Patients who could not be followed up during the trial

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the performance of patent foramen ovale (PFO) device developed by Lifetech Technology (Shenzhen) Co., LTD

A vizsgálat csoportja

  • Intervention armA vizsgált kezelés

    Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form

    Kezelés: Iris FIT™ PFO closure system

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multi-Center, Single-Group Goal Value Clinical Trial to Revaluate the Safety and Efficacy of Patent Foramen Ovale Occluders
A regiszteradat frissítve
2023. március 14.